期刊
AMERICAN JOURNAL OF GASTROENTEROLOGY
卷 115, 期 1, 页码 128-137出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.14309/ajg.0000000000000503
关键词
-
资金
- Janssen Canada
- Abbvie Canada
- Shire Canada
- Takeda Canada
- Ferring
- Merck Canada
- Abbvie
- Janssen
- Merck
- Shire
- Canadian Institutes of Health Research
- Crohn's and Colitis Canada
- Canadian Association of Gastroenterology
- Career Enhancement Program of the Canadian Child Health Clinician Scientist Program
- Canadian Institutes of Health Research (CIHR)
- Canadian Association of Gastroenterology (CAG)
OBJECTIVES: The prevalence of inflammatory bowel disease (IBD) is increasing. The total direct costs of IBD have not been assessed on a population-wide level in the era of biologic therapy. DESIGN: We identified all persons with IBD in Manitoba between 2005 and 2015, with each matched to 10 controls on age, sex, and area of residence. We enumerated all hospitalizations, outpatient visits and prescription medications including biologics, and their associated direct costs. Total and per capita annual IBD-attributable costs and health care utilization (HCU) were determined by taking the difference between the costs/HCU accrued by an IBD case and their controls. Generalized linear modeling was used to evaluate trends in direct costs and Poisson regression for trends in HCU. RESULTS: The number of people with IBD in Manitoba increased from 6,323 to 7,603 between 2005 and 2015. The total per capita annual costs attributable to IBD rose from $3,354 in 2005 to $7,801 in 2015, primarily driven by an increase in per capita annual anti-tumor necrosis factor costs, which rose from $181 in 2005 to $5,270 in 2015. There was a significant decline in inpatient costs for CD ($99 +/- 25/yr. P < 0.0001), but not for ulcerative colitis ($8 increase +/-$18/yr, P = 0.63). DISCUSSION: The direct health care costs attributable to IBD have more than doubled over the 10 years between 2005 and 2015, driven mostly by increasing expenditures on biological medications. IBD-attributable hospitalization costs have declined modestly over time for persons with CD, although no change was seen for patients with ulcerative colitis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据